BNA’s Health Care Daily Report™ sets the standard for reliable, high-intensity coverage of breaking health care news, covering all major legal, policy, industry, and consumer developments in a...
Sept. 30 — The chairman of the House Energy and Commerce Committee predicted Sept. 30 that drug prices would go down if the House-passed 21st Century Cures bill (H.R. 6) becomes law.
If enacted, the bill would expedite the approval of drugs and devices, which would reduce research and development costs and ultimately bring down prices, Rep. Fred Upton (R-Mich.) said at a forum on the legislation.
In July, the House voted overwhelmingly (344–77) to pass the bill (133 HCDR, 7/13/15), which now moves to the Senate for consideration.
Upton and Rep. Diana DeGette (D-Colo.), both of whom championed the bill in the House, spoke about the legislation's impact on medical research funding at a forum organized by the law firm Dentons. DeGette said getting a companion billdebated on the Senate floor this fall may be difficult. Since 2016 is a presidential election year, DeGette said she'd like to get a Senate version of the bill passed as quickly as possible and she welcomed senators' input on the legislation.
The forum's moderator, Bruce Merlin Fried, an attorney with Dentons' health-care practice in the firm's Washington office, said privacy advocates have raised concerns about the cures legislation. There are provisions in the bill “that would allow protected health information to be used for research purposes” and privacy advocates are anxious that it could undercut an individual's ability to control his or her own personal medical information, according to Fried.
Upton said the cures legislation includes adequate privacy protections. Individuals' personal health data “should be fine,”Upton said, adding, “At the same time, let's use some of the data” to further medical research and advance science.
DeGette said the bill would allow for the establishment of a centralized database for patient data. Many researchers believe that such a database is critical “to be able to utilize precision medicine and to be able to really find cures that will impact” patients, DeGette said.
The Colorado lawmaker also said that if patients are told that the personal data provisions in the cures bill would follow Health Insurance Portability and Accountability Act procedures and that other steps will be taken to protect individual privacy, “the vast number of patients” will consent to allowing their information to be used for research.
However, provisions in the legislation about centralizing data could fleshed out more, according to DeGette, adding that “we think this is a place where the Senate could really bring a great imprint on to this bill.”
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)